Vyvgart (efgartigimod alfa-fcab) is a prescription drug that’s used to treat myasthenia gravis (MG). Vyvgart comes as a liquid solution that’s given as an intravenous (IV) infusion.

Among 47 patients with any of several forms of idiopathic inflammatory myositis (IIM) who took efgartigimod (Vyvgart Hytrulo) ...

Vyvgart (efgartigimod alfa-fcab) is a brand-name intravenous (IV) infusion prescribed for some adults with generalized myasthenia gravis. As with other drugs, Vyvgart can cause side effects ...

Vyvgart (efgartigimod alfa-fcab) is a prescription drug used to treat myasthenia gravis in certain adults. Vyvgart’s cost may depend on factors such as your dosage, whether you have health ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...

WEDNESDAY, April 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the ...

75% of gMG patients on Vyvgart showed sustained MG-ADL improvements over 126 weeks. Vyvgart Hytrulo improved functional and QoL scores in gMG and CIDP with no rise in infections over nine ...